title: Drugs derived from phage display: from candidate identification to clinical practice.
abstract: Phage display, one of today’s fundamental drug discovery technologies, allows identification of a broad range of biological drugs, including peptides, antibodies and other proteins, with the ability to tailor critical characteristics such as potency, specificity and cross-species binding. Further, unlike in vivo technologies, generating phage display-derived antibodies is not restricted by immunological tolerance. Although more than 20 phage display-derived antibody and peptides are currently in late-stage clinical trials or approved, there is little literature addressing the specific challenges and successes in the clinical development of phage-derived drugs. This review uses case studies, from candidate identification through clinical development, to illustrate the utility of phage display as a drug discovery tool, and offers a perspective for future developments of phage display technology.
authors.forename: Andrew E
authors.initials: AE
authors.lastname: Nixon
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: Sexton
authors.forename: Robert C
authors.initials: RC
authors.lastname: Ladner
mesh_terms: D000818:Animals; D055808:Drug Discovery / Q000379:methods* / Q000639:trends*; D006801:Humans; D057127:Single-Chain Antibodies / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use
chemical_list: D057127:Single-Chain Antibodies